Pan-RAF inhibitors, such as belvarafenib, which can target BRAFV600E, the BRAF wild-type, and CRAF have shown anti-tumor efficacy in NRAS mutant melanomas in a phase 1 dose escalation study with an ORR of 44% [97]. This evidence concerns the gene NRAS and neoplasm.